Big Pharma

Why Santen ends Neurim-style SPCs

In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.

• The right recipe for the repurposing omelette 14-08-2020
• No SPC crown for Royalty Pharma 10-07-2020
• Could good intentions lead to future danger? 10-07-2020
• SPCs: a deep dive into CJEU case law 23-06-2020
• Will the EU’s SPC manufacturing waiver weaken European pharma’s IP? 20-05-2020

More big pharma features